- GoSilico’s software creates “digital twins” of downstream processes and is increasingly used to enhance process development by simulation
- 81% of mechanistic modelling users surveyed by Cytiva identified this as the future process development of chromatography
- Compared to traditional development approaches, mechanistic modelling saves significant time and materials on process development, since physical experiments become inessential
June 02, 2021 – Press Release
Global life sciences leader Cytiva has acquired the German scientific software maker GoSilico, in a move that will differentiate Cytiva as a premier partner in bioprocessing.
Olivier Loeillot, Vice President, Cytiva, says: “The powerfully innovative digital solution created by GoSilico will bring great value to our customers, who can use mechanistic models to improve their decisions, accelerate their process development and more quickly bring new therapies to market. GoSilico’s expert team and solution are a fantastic addition to Cytiva’s longtime leadership in chromatography, process development, and overall bioprocessing.”
Thiemo Huuk, co-founder and co-CEO of GoSilico, says: “Our entire team is excited to join the Cytiva family. With Cytiva’s global presence and broad base of customers, our mechanistic modelling technology will reach more drugmakers, ultimately enabling a more robust process development and a more efficient path to bring new therapies to patients.”
Process development is an intense and time-consuming part of making a therapy or medicine. GoSilico’s simulation software is used to build digital twins of downstream processing. Compared to traditional methods, such as one factor at a time – which can take approximately 13 weeks – or design of experiments – which often takes approximately four weeks – the simulation can reveal how process parameters affect attributes. The result is a scalable and robust solution within about one week, a reduction in experiment materials and, more impactfully, more confident decision-making.
A survey commissed by Cytiva and conducted by a third party UK-based global market research agency, Jigsaw Research in December 2020, found that out of 104 respondants, 66% said mechanistic modelling will enable them to get to market significantly faster.
73% of survey respondents said they used mechanistic modelling as a tool to deliver more robust results and 70% said the simulations increased their process understanding. In terms of purpose, most respondents use mechanistic modelling for mAb therapies, but also for emerging modalities such as gene therapy or viral vectors. 81% of respondents viewed the technology as “the future of process development.”
GoSilico’s products will continue to be known as GoSilico ChromX and GoSilico DSPX for the immediate future and will be integrated into Cytiva immediately.
More on mechanistic modelling
Meet GoSilico’s co-founder and co-CEO Tobias Hahn in an episode of Cytiva’s Discovery Matters podcast about mechanistic modelling
BioProcess/Chromatography portfolio page: Chromatography Columns, Systems & Supplies | Cytiva
Further applications: Bioprocessing 4.0 – GoSilico Solutions
Explanatory video on GoSilico’s simulation technology
Cytiva is a global life sciences leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
Svenja von Bartenwerffer